Biogen says its Chief Executive Michel Vounatsos will step down and the drugmaker will pull back on selling its Alzheimer's treatment Aduhelm after struggles with its launch
said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.
Biogen last month decided to withdraw its marketing application for Aduhelm in Europe after failing to convince the European regulator of the treatment's benefits.The company said it will retain minimal resources to make Aduhelm available to patients currently taking the drug in the United States. A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Change at the top for Biogen after Alzheimer's drug flopsBiogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled. The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed.
Read more »
Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug StrugglesMichel Vounatsos’s resignation comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.
Read more »
Change at the top for Biogen after Alzheimer's drug flopsBiogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled. The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed.
Read more »
Biogen CEO Michel Vounatsos to Step Aside After Alzheimer’s Drug StrugglesMichel Vounatsos’s resignation comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.
Read more »
Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm TreatmentPeople with Alzheimer’s disease will be less likely to receive Aduhelm because of the company’s decision to slash commercial support for the drug in the face of restricted reimbursement by the U.S. Medicare program and other insurers.
Read more »
Match Group's Shar Dubey to step down as CEOMatch Group's Shar Dubey will step down as chief executive officer, the Tinder owner said on Tuesday, and will be succeeded by Bernard Kim, mobile gaming maker Zynga's president, effective May 31.
Read more »